Cingulate Inc (CING) AI Stock Analysis

• Market Cap: $13.79M
• Dividend Yield: N/A
• Average Volume (3M): 89.69K
• Price to Earnings (P/E): ―
• Beta (1Y): 5.51
• Revenue Growth: N/A
• EPS Growth: 95.52%
• Country: US
• Employees: 13
• Sector: Healthcare
• Sector Strength: 70
• Industry: Biotechnology
• EPS (TTM): -16.32
• Shares Outstanding: 3,768,400
• 10 Day Avg. Volume: 96,901
• 30 Day Avg. Volume: 89,695
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -0.80
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $13.33
• Price Target Upside: 264.21% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

Cingulate Inc.'s overall score reflects its poor financial health, with significant losses and lack of revenue. While technical analysis shows some neutrality, the negative valuation metrics are concerning. However, recent corporate events provide a potential upside with new funding and regulatory progress, which could help address the company's financial challenges in the future.

Positive Factors

Market Opportunity

Considering the ongoing stimulant shortages, especially for generic stimulant products, and that CTx-1301 only requires one dose, daily, the commercial opportunity for Cingulate is attractive.

Product Efficacy

CTx-1301 demonstrated a potential best-in-class onset and duration for ADHD, making it a competitive differentiator amidst ongoing stimulant shortages.

Regulatory Progress

Cingulate has completed its final FDA-required clinical program for CTx-1301, which is a significant step towards FDA approval for the treatment of ADHD.

Negative Factors

Clinical Study Results

Despite achieving clinical meaningfulness, the Phase 3 study did not achieve statistical significance as it was not powered for this objective.

Financial Performance

Cingulate reported a net loss of $6.1M for the fourth quarter and $15.5M for the year, which could be a concern for investors.

Operating Expenses

Operating expenses in the fourth quarter were significantly higher than expected, potentially affecting financial performance.

Cingulate Inc Business Overview & Revenue Model

Company Description

Cingulate Inc. is a biopharmaceutical company focused on the development, manufacturing, and commercialization of innovative therapies for the treatment of central nervous system disorders. Operating primarily in the healthcare and pharmaceutical sectors, the company is dedicated to addressing unmet medical needs through its portfolio of proprietary drug candidates, with a particular emphasis on attention deficit/hyperactivity disorder (ADHD) and anxiety disorders.

How the Company Makes Money

Cingulate Inc. generates revenue through the research, development, and eventual commercialization of its proprietary drug formulations. The company focuses on advancing its product candidates through clinical trials and obtaining regulatory approvals, which would enable them to market these drugs to healthcare providers and patients. Revenue streams are expected to include sales of approved medications, licensing agreements, and potential partnerships with other pharmaceutical companies. Additionally, Cingulate may engage in collaborative research arrangements that provide funding and milestone payments, contributing to its financial inflows.

Cingulate Inc Financial Statement Overview

Summary

Cingulate Inc. faces significant financial challenges with zero revenue, consistent losses, and negative cash flows, indicating financial distress and reliance on external funding.

Income Statement

Cingulate Inc. has consistently reported zero revenue across the years, indicating no sales or commercialization activities. The company is experiencing significant losses, with negative EBIT and Net Income frequently worsening year over year. There is no revenue growth, and both EBIT and EBITDA margins are negative, highlighting operational inefficiencies and financial distress.

Balance Sheet

The company has no debt as of the latest report, which is a positive aspect. However, the stockholders' equity is zero, indicating a lack of financial cushion. Historical data shows negative equity in some years, highlighting financial instability. The absence of liabilities may be misleading due to the lack of assets compared to the company’s size and industry norms.

Cash Flow

Operating cash flow is consistently negative, reflecting ongoing cash burn without revenue generation. The free cash flow is also negative, indicating that the company is not generating sufficient cash to cover its operational needs. There is no growth in free cash flow, and the heavy reliance on financing cash flow suggests dependency on external funding to sustain operations.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
-3.85B	0.00	0.00	0.00	0.00	0.00
	Gross Profit
-10.34B	0.00	-582.92K	-621.99K	-808.44K	-842.35K
	EBIT
-6.58B	-15.64M	-22.76M	-17.50M	-20.68M	-7.08M
	EBITDA
-15.71M	-15.64M	-22.95M	-17.05M	-19.87M	-6.29M
	Net Income Common Stockholders
-3.24B	-15.55M	-23.53M	-17.85M	-20.74M	-7.28M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.74M	0.00	52.42K	5.36M	16.49M	1.20M
	Total Assets
7.16M	17.41B	3.49M	11.41M	22.89M	5.79M
	Total Debt
5.78M	0.00	3.14M	5.53M	881.13K	2.05M
	Net Debt
4.04M	0.00	3.08M	170.01K	-15.61M	848.99K
	Total Liabilities
7.08M	0.00	10.36M	7.52M	2.04M	4.50M
	Stockholders Equity
81.61K	0.00	-6.87M	-69.41M	20.84M	1.29M
Cash Flow		Free Cash Flow
-17.13M	-18.45M	―	-16.04M	-11.25M	-7.21M
	Operating Cash Flow
-16.93M	-18.45M	-15.03M	-15.88M	-10.43M	-6.81M
	Investing Cash Flow
-200.30K	-212.00K	-224.00K	-152.65K	-814.74K	-384.17K
	Financing Cash Flow
25.19M	30.82M	9.96M	4.90M	26.54M	7.97M

Cingulate Inc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 3.66
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CING, the sentiment is Negative. The current price of 3.66 is below the 20-day moving average (MA) of 3.95, below the 50-day MA of 4.09, and below the 200-day MA of 4.78, indicating a bearish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 56.17 is Neutral, neither overbought nor oversold. The STOCH value of 78.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CING.

Cingulate Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	48 Neutral	$6.25B	1.14	-46.26%	2.69%	19.24%	1.75%
CING	37 Underperform	$13.79M	―	-5305.02%	―	―	95.52%
PHGE	35 Underperform	$13.98M	―	-189.64%	―	―	45.24%
HOOK	34 Underperform	$9.48M	―	-61.68%	―	118.32%	61.16%
GLYC	31 Underperform	$12.40M	―	-173.25%	―	-100.00%	-0.58%
NXTC	30 Underperform	$7.56M	―	-61.87%	―	―	11.66%
CARM	23 Underperform	$8.32M	―	-362.79%	―	31.59%	57.94%

Cingulate Inc Corporate Events

Cingulate Inc Secures $3M Grant for Anxiety Drug

On April 8, 2025, Cingulate Inc. entered into a Grant Agreement with a private foundation to receive a $3 million grant for the development of CTx-2103, a once-daily formulation of buspirone for anxiety treatment. This funding, distributed in three $1 million payments, will accelerate Cingulate’s pipeline and validate its PTR technology, potentially reducing reliance on benzodiazepines and addressing a significant market need in the $5.5 billion U.S. anxiety market.

Spark’s Take on CING Stock

According to Spark, TipRanks’ AI Analyst, CING is a Neutral.

Cingulate Inc.’s stock score is primarily impacted by its poor financial performance, with persistent losses and negative cash flows. However, recent corporate developments, including progress towards FDA approval for CTx-1301, provide a significant positive outlook. Technical indicators show neutral market momentum, but valuation remains a concern due to financial losses and lack of dividends.

To see Spark’s full report on CING stock, click here.

Cingulate Inc. Advances Towards FDA Approval for CTx-1301

On March 4, 2025, Cingulate Inc. announced the safety results from its final Phase 3 trials for CTx-1301, a novel, once-daily stimulant medication for ADHD, which showed no serious adverse events and consistent safety profiles. The results, submitted to the FDA ahead of an April 2 meeting, mark a significant step towards filing for FDA approval mid-2025, potentially positioning Cingulate as a leader in ADHD treatment with a product that addresses unmet needs in the market.